E2 ModeratePreliminaryPEM unclearCase-ControlPeer-reviewedMachine draft
The distribution of white blood cell fat oxidation in health and disease.
Pendergast, D R, Fisher, N M, Meksawan, K et al. · Journal of inherited metabolic disease · 2004 · DOI
Quick Summary
This study looked at how white blood cells use fat for energy in different groups of people, including those with ME/CFS. Researchers measured fat burning in blood cells from healthy controls, people with ME/CFS, people with other conditions, and athletes. They found that people with ME/CFS had unusually high fat oxidation in their white blood cells, while people with a genetic disorder (CPT II deficiency) had very low fat oxidation.
Why It Matters
This study provides a potential biological marker—abnormally high white blood cell fat oxidation—that distinguishes ME/CFS patients from healthy controls and other disease groups. Understanding metabolic abnormalities in ME/CFS may help explain energy metabolism dysfunction and could eventually support diagnosis or guide treatment approaches targeting cellular energy production.
Observed Findings
- CFS patients showed significantly elevated white blood cell fat oxidation compared to sedentary healthy controls.
- CPT II-deficient patients demonstrated severely reduced fat oxidation (0.09 nmol/h per 10⁹ WBC), establishing the measurement's ability to detect metabolic abnormalities.
- Elite runners had the highest fat oxidation (0.59 nmol/h per 10⁹ WBC), approximately 2.2 times higher than controls.
- Patients with MS, obesity, or eating disorders showed fat oxidation similar to healthy sedentary controls.
- Acute exercise and sex did not significantly affect white blood cell fat oxidation.
Inferred Conclusions
- Genetic factors are the primary determinant of individual fat oxidation rates in white blood cells, distinct from acute exercise effects.
- White blood cell fat oxidation can serve as a measurable marker of genetic predisposition for fat metabolism, as demonstrated in both CPT II-deficient patients and elite runners.
- Abnormally high fat oxidation (>35 nmol/h per 10⁹ WBC) may be a characteristic metabolic feature of ME/CFS.
- The genetic basis of fat oxidation capacity varies widely across disease states and athletic phenotypes.
Remaining Questions
- Is the elevated fat oxidation in ME/CFS patients present across larger, more diverse patient cohorts, and does it correlate with disease severity or specific symptom profiles?
What This Study Does Not Prove
This study does not prove that elevated fat oxidation causes ME/CFS or is responsible for ME/CFS symptoms; it only identifies an association. The very small ME/CFS sample size (n=6) limits generalizability. The study also does not establish whether this marker is specific to ME/CFS or whether it correlates with symptom severity, exercise capacity, or post-exertional malaise.
Tags
Symptom:Fatigue
Biomarker:MetabolomicsBlood Biomarker
Method Flag:PEM Not DefinedWeak Case DefinitionSmall SampleExploratory Only
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →